- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02926664
Delta qSOFA for Risk Stratification in Emergency Infected Patients (DELTASCREEN)
Prognostic Value of Quick Sequential Organ Failure Assessment Kinetics After Fluids Challenge in the Emergency Department
Study Overview
Detailed Description
qSOFA has been reported as a good tool for risk stratification in the ED for patients with infection.
However, it is not clear whether qSOFA remains stable during the ED stay, nor whether its kinetics can have prognostic added value.
Patients with a qSOFA of at least 2 in the ED, and suspicion of infection will be included.
After treatment is initiated and fluids challenge performed, we will collect qSOFA value at 1 hour and 3 hours.
Our hypothesis is that a decrease in qSOFA between H0 and H3 is associated with better outcome. We assume that 50% of patients will have a deltaqSOFA >0, with an overall mortality of 23% (according to previous cohort). Under the hypothesis of difference of at least 15% in mortality between the two groups (DeltaqSOFA > 0 and Delta qSOFA<=0), with a power of 90% and an alpha of 0.05, we need to recruit 322 patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium
- Cliniques St Luc
-
-
-
-
-
Nimes, France
- CHU Nîmes
-
Paris, France
- Hôpital Pitié-Salpêtrière
-
Paris, France
- Hôpital Europeén Georges Pompidou
-
Paris, France
- Hôpital Tenon
-
Paris, France
- COCHIN
-
Paris, France
- Lariboisière
-
Paris, France
- Saint Antoine
-
Strasbourg, France
- CHU Strasbourg
-
-
-
-
-
Barcelona, Spain
- Hospital Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- suspicion of infection by the emergency physicians
- at least two of the following criteria : respiratory rate <= 22, systolic blood pressure <= 100 mmHg and altered mental status
Exclusion Criteria:
- Infection ruled out by the expert after chart review
- patient who refuse to participate
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
In-hospital mortality
Time Frame: 60 days
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ICU admission more than 72 hours
Time Frame: 60 days
|
60 days
|
|
ICU admission
Time Frame: 60 days
|
60 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yonathan Freund, Emergency Department - hopital pitie salpetriere, Paris, France
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DeltaSCREEN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.